Logo image of XNCR

XENCOR INC (XNCR) Stock Overview

NASDAQ:XNCR - US98401F1057 - Common Stock

8.01 USD
-0.4 (-4.76%)
Last: 8/25/2025, 4:30:02 PM
8.01 USD
0 (0%)
After Hours: 8/25/2025, 4:30:02 PM

XNCR Key Statistics, Chart & Performance

Key Statistics
52 Week High27.24
52 Week Low6.92
Market Cap571.27M
Shares71.32M
Float70.39M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.4
PEN/A
Fwd PEN/A
Earnings (Next)11-04 2025-11-04/amc
IPO12-03 2013-12-03
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


XNCR short term performance overview.The bars show the price performance of XNCR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

XNCR long term performance overview.The bars show the price performance of XNCR in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of XNCR is 8.01 USD. In the past month the price decreased by -11.3%. In the past year, price decreased by -54.2%.

XENCOR INC / XNCR Daily stock chart

XNCR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.6 366.65B
AMGN AMGEN INC 13.23 155.30B
GILD GILEAD SCIENCES INC 14.75 141.64B
VRTX VERTEX PHARMACEUTICALS INC 22.96 99.72B
REGN REGENERON PHARMACEUTICALS 12.54 60.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.15B
ARGX ARGENX SE - ADR 73.07 41.45B
ONC BEONE MEDICINES LTD-ADR 6.25 36.69B
INSM INSMED INC N/A 27.12B
BNTX BIONTECH SE-ADR N/A 25.26B
NTRA NATERA INC N/A 22.30B
BIIB BIOGEN INC 8.52 19.99B

About XNCR

Company Profile

XNCR logo image Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 250 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Company Info

XENCOR INC

465 N. Halstead St., Suite 200

Pasadena CALIFORNIA 91016 US

CEO: Bassil I. Dahiyat

Employees: 250

XNCR Company Website

XNCR Investor Relations

Phone: 16263055900

XENCOR INC / XNCR FAQ

What is the stock price of XENCOR INC today?

The current stock price of XNCR is 8.01 USD. The price decreased by -4.76% in the last trading session.


What is the ticker symbol for XENCOR INC stock?

The exchange symbol of XENCOR INC is XNCR and it is listed on the Nasdaq exchange.


On which exchange is XNCR stock listed?

XNCR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for XENCOR INC stock?

18 analysts have analysed XNCR and the average price target is 26.29 USD. This implies a price increase of 228.26% is expected in the next year compared to the current price of 8.01. Check the XENCOR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is XENCOR INC worth?

XENCOR INC (XNCR) has a market capitalization of 571.27M USD. This makes XNCR a Small Cap stock.


How many employees does XENCOR INC have?

XENCOR INC (XNCR) currently has 250 employees.


What are the support and resistance levels for XENCOR INC (XNCR) stock?

XENCOR INC (XNCR) has a resistance level at 8.35. Check the full technical report for a detailed analysis of XNCR support and resistance levels.


Is XENCOR INC (XNCR) expected to grow?

The Revenue of XENCOR INC (XNCR) is expected to grow by 119.14% in the next year. Check the estimates tab for more information on the XNCR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy XENCOR INC (XNCR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does XENCOR INC (XNCR) stock pay dividends?

XNCR does not pay a dividend.


When does XENCOR INC (XNCR) report earnings?

XENCOR INC (XNCR) will report earnings on 2025-11-04, after the market close.


What is the Price/Earnings (PE) ratio of XENCOR INC (XNCR)?

XENCOR INC (XNCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.4).


What is the Short Interest ratio of XENCOR INC (XNCR) stock?

The outstanding short interest for XENCOR INC (XNCR) is 13.17% of its float. Check the ownership tab for more information on the XNCR short interest.


XNCR Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

XNCR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to XNCR. The financial health of XNCR is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XNCR Financial Highlights

Over the last trailing twelve months XNCR reported a non-GAAP Earnings per Share(EPS) of -2.4. The EPS increased by 16.96% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -20.23%
ROE -28.67%
Debt/Equity 0.15
Chartmill High Growth Momentum
EPS Q2Q%61.68%
Sales Q2Q%157.12%
EPS 1Y (TTM)16.96%
Revenue 1Y (TTM)17.52%

XNCR Forecast & Estimates

18 analysts have analysed XNCR and the average price target is 26.29 USD. This implies a price increase of 228.26% is expected in the next year compared to the current price of 8.01.

For the next year, analysts expect an EPS growth of 23.89% and a revenue growth 119.14% for XNCR


Analysts
Analysts84.44
Price Target26.29 (228.21%)
EPS Next Y23.89%
Revenue Next Year119.14%

XNCR Ownership

Ownership
Inst Owners113.14%
Ins Owners1.1%
Short Float %13.17%
Short Ratio13.09